Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Virus-based gene therapy research, and Cancer Cells and Metastasis.
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site
Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Novel chimeric antigen receptors for the effective and safe treatment of NY‐BR‐1 positive breast cancer
P06.05.A INTRACEREBROVENTRICULAR TCR-TRANSGENIC T CELL THERAPY TO TREAT GLIOBLASTOMA (INVENT4GB)
Abstract 1769: A combination approach of a cellular library and single cell microfluidics analysis for the rapid selection of CAR-T cells
A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
Maxcyte flow electroporation technology: a safe, reliable and effective method for engineering car T cells
Cost of decentralized <scp>CAR</scp> T‐cell production in an academic nonprofit setting
Reply to: Comments on “Cost of decentralized <scp>CAR</scp> T cell production in an academic non‐profit setting”
1603P Can we reduce the acquisition cost of CAR T cell therapies?
PCN335 COST OF DECENTRALIZED CAR T CELL PRODUCTION: CURRENT STATUS IN A EUROPEAN NON-PROFIT SETTING
PCN209 The Acquisition Cost and Efficiency of CAR T Cell Therapies: CAN They be Improved By Decentralized Manufacturing?
Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
Abstract A042: A novel nonviral, nonintegrative DNA vector system for T-cell engineering
Abstract 3573: Novel DNA vectors encoding a chimeric antigen receptor mediate long term expression without genomic integration
Abstract B054: Evaluation of NY-BR-1 as a suitable antigen for CAR based immunotherapy